Longevity Pulse
Sign In

All Articles

41 articles

All TopicsCancerHeart DiseaseAlzheimer'sParkinson'sDiabetesGut HealthNutritionStrength & FitnessSupplements & PeptidesStem CellsReversing AgingAuto-ImmunityAdvanced TherapiesSleep & Mindfulness
📋All Types🔬Papers📖Reviews▶️Videos🎙️Podcasts🧪Trials💊Approvals📰Press Releases📚Tutorials🎬Animations
FDA Listing Reports New Drug Combinations for Colon and Breast Cancer
Cancer Research

FDA Listing Reports New Drug Combinations for Colon and Breast Cancer

Three reported cancer approvals highlight tumor-guided treatment, but incomplete dates and missing trial data require verification.

Drug Approval
Oct 14, 2026 0
FDA Approves Tavapadon for Parkinson's Disease in Adults
Brain Health

FDA Approves Tavapadon for Parkinson's Disease in Adults

Juvmo (tavapadon) is a newly FDA-approved therapy for Parkinson's disease in adults.

Drug Approval
Oct 2, 2026 0
FDA Approves Seven New Brain-Health Drugs Including First At-Home Lecanemab Dose
Brain Health

FDA Approves Seven New Brain-Health Drugs Including First At-Home Lecanemab Dose

A wave of FDA approvals targets Alzheimer's, narcolepsy, and rare neurological disorders — including a landmark at-home dosing option for lecanemab.

Drug Approval
Sep 21, 2026 0
FDA Approves Tirzepatide to Cut Major Cardiovascular Risk in Type 2 Diabetes
Metabolic Health

FDA Approves Tirzepatide to Cut Major Cardiovascular Risk in Type 2 Diabetes

Mounjaro (tirzepatide) gains FDA approval to reduce heart attack, stroke, and cardiovascular death in high-risk adults with type 2 diabetes.

Drug Approval
Sep 20, 2026 0
FDA Approves Tirzepatide for CV Risk and Orforglipron for Weight Loss in Back-to-Back Wins
Metabolic Health

FDA Approves Tirzepatide for CV Risk and Orforglipron for Weight Loss in Back-to-Back Wins

Two landmark FDA approvals in two weeks reshape the metabolic health landscape for obesity, type 2 diabetes, and cardiovascular risk.

Drug Approval
Sep 18, 2026 0
FDA Approves Repotrectinib for ROS1-Positive Lung Cancer in 2026
Cancer Research

FDA Approves Repotrectinib for ROS1-Positive Lung Cancer in 2026

Augtyro (repotrectinib) gains FDA approval for locally advanced or metastatic ROS1-positive NSCLC, offering a new targeted therapy option.

Drug Approval
Jul 23, 2026 0
FDA Approves First Oral PCSK9 Inhibitor Lipfendra to Lower LDL Cholesterol
Heart Health

FDA Approves First Oral PCSK9 Inhibitor Lipfendra to Lower LDL Cholesterol

Lipfendra (enlicitide) becomes the first oral PCSK9 inhibitor approved for adults with high LDL cholesterol, expanding cardiovascular risk reduction options.

Drug Approval
Jul 17, 2026 0
Leqembi Gets At-Home Starting Dose Approval in Alzheimer's Milestone
Brain Health

Leqembi Gets At-Home Starting Dose Approval in Alzheimer's Milestone

The FDA authorizes an at-home starting dose for Leqembi, making early Alzheimer's treatment more accessible for patients and caregivers.

Drug Approval
Jul 17, 2026 0
Six Major Cancer Drug Approvals Reshape Treatment for Breast, Lung and Ovarian Cancers
Cancer Research

Six Major Cancer Drug Approvals Reshape Treatment for Breast, Lung and Ovarian Cancers

The FDA approved six oncology drugs in early-to-mid 2026, targeting breast, lung, ovarian, and lymphoma cancers with novel mechanisms.

Drug Approval
Jul 17, 2026 0
FDA Approves First Oral GLP-1 Pill for Obesity and Once-Weekly Insulin for Diabetes
Metabolic Health

FDA Approves First Oral GLP-1 Pill for Obesity and Once-Weekly Insulin for Diabetes

Orforglipron and insulin icodec mark a new era in metabolic disease treatment, offering pill-based and weekly injection alternatives to daily regimens.

Drug Approval
Jul 12, 2026 0
FDA Approves Utebzi for Complicated Urinary Tract Infections Including Pyelonephritis
Metabolic Health

FDA Approves Utebzi for Complicated Urinary Tract Infections Including Pyelonephritis

Tebipenem pivoxil becomes the first oral carbapenem approved in the US, offering a non-IV option for serious UTIs.

Drug Approval
Jun 21, 2026 0
FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy
Heart Health

FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy

Myqorzo (aficamten) wins FDA approval for symptomatic obstructive HCM, offering a novel cardiac myosin inhibitor option for patients.

Drug Approval
Jun 14, 2026 0
Page 1 of 4Next